MEVRPO-1
Research type
Research Study
Full title
A phase 3, randomized, open-label study of PF-06821497 (Mevrometostat) in combination with enzalutamide compared with enzalutamide or docetaxel in participants with metastatic castration resistant prostate cancer previously treated with abiraterone acetate (MEVPRO-1)
IRAS ID
1010161
Contact name
Cheryl Becker
Contact email
Sponsor organisation
Pfizer Inc
Clinicaltrials.gov Identifier
Research summary
Pfizer MEVPRO-1 (C2321014) is a randomized, open-label, multi-center clinical trial evaluating whether combining the study medicine (PF-06821497) with enzalutamide is safe and effective compared to physician’s choice of either second-line androgen receptor (AR) directed therapy with enzalutamide or docetaxel (chemotherapy) for treating metastatic castration-resistant prostate cancer (mCRPC) after progression on prior abiraterone acetate treatment. The primary objective of this clinical trial is to assess the radiographic progression free survival (rPFS) of the combination of PF-06821497 plus enzalutamide versus physician's choice of enzalutamide or docetaxel.
REC name
West of Scotland REC 1
REC reference
24/WS/0164
Date of REC Opinion
7 Feb 2025
REC opinion
Further Information Favourable Opinion